Parameter | Developmental stage | Control Merged | Control Montanide | Control SjGST | CHI-GST (% reduction) | TSP1-GSTÂ +Â TSP2 (% reduction) | RPP0 (% reduction) | PK4 (% reduction) |
---|---|---|---|---|---|---|---|---|
Ingested blood (mg) | Males | 3.7 ± 0.5 | 3.7 ± 0.1 | 3.7 ± 0.7 | 3.6 ± 0.1 (2.7) | 3.8 ± 0.2 | 4.1 ± 0.2 | 3.4 ± 0.3 (8.1) |
Females | 13.0 ± 1.1 | 13.0 ± 3.1 | 13.0 ± 1.2 | 13.3 ± 0.6 | 13.3 ± 1.2 | 12.8 ± 2.0 (1.5) | 12.5 ± 0.2 (3.8) | |
Nymphs-3 | 3.3 ± 0.5 | 3.2 ± 0.4 | 3.5 ± 0.5 | 3.0 ± 0.5 (9.1) | 3.9 ± 0.4 | 3.3 ± 0.5 | 3.1 ± 0.7 (6.1) | |
Mortality (%) | Males | 0.6 ± 1.4 | 0 ± 0 | 1.1 ± 1.8 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Females | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 2.1 ± 3.0 (2.1) | 2.1 ± 3.0 (2.1) | |
Nymphs-3 | 4.3 ± 2.9 | 6.0 ± 2.0 | 2.7 ± 2.7 | 1.3 ± 1.0 | 10.0 ± 12.9 (5.7) | 1.4 ± 1.0 | 4.1 ± 3.5 | |
Moulting (%) | Nymphs-3 | 60.5 ± 8.9 | 61.1 ± 9.8 | 59.8 ± 9.0 | 42.3 ± 3.0 (30.1)** | 45.5 ± 15.2 (24.8)** | 38.1 ± 10.7 (37.1)** | 31.8 ± 19.8 (47.4)** |
Oviposition (no. eggs/female) | Females | 66.4 ± 6.0 | 67.2 ± 8.5 | 65.6 ± 3.5 | 61.6 ± 3.4 (7.2) | 50.0 ± 4.5 (24.7)** | 48.0 ± 6.1 (27.7)** | 54.2 ± 6.0 (18.4)** |
Fertility (no. nymphs/female) | Females | 55.5 ± 5.7 | 56.8 ± 6.3 | 54.3 ± 5.3 | 53.7 ± 1.6 (3.2) | 32.5 ± 4.4 (41.4)** | 36.6 ± 2.7 (34.1)** | 41.5 ± 6.7 (25.2)** |
Efficacy (%) | Â | Â | Â | Â | 30.2 | 56.0 | 57.5 | 57.8 |